Primary Outcome Measures: | |
1. |
Study A: Proportion of participants with improvement (reduction) in weekly average of daily worst-itch numerical rating scale (WI-NRS) by ≥4 from baseline to Week 12 [ Time Frame: Baseline to Week 12 ]
WI-NRS is a patient reported outcome (PRO) comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
2. |
Study B: Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 12 [ Time Frame: Baseline to Week 12 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
Secondary Outcome Measures: | |
1. |
Study A: Proportion of participants who scored "none" or "mild" in Patient Global Impression of Severity (PGIS) of pruritus at Week 12 [ Time Frame: Week 12 ]
The PGIS of pruritus is a one-item categorical scale that asks participants to provide the overall self-assessment of their pruritus severity on a 4-point scale for the past week. Response choices are: "None", "Mild", "Moderate", "Severe". |
2. |
Study A: Absolute change from baseline in weekly average of daily WI-NRS at Week 12 [ Time Frame: Baseline to Week 12 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
3. |
Study A: Percent change from baseline in weekly average of daily WI-NRS at Week 12 [ Time Frame: Baseline to Week 12 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
4. |
Study A; Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 24 [ Time Frame: Baseline to Week 24 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
5. |
Study A: Proportion of participants who scored "none" or "mild" in PGIS of pruritus at Week 24 [ Time Frame: Week 24 ]
The PGIS of pruritus is a one-item categorical scale that asks participants to provide the overall self-assessment of their pruritus severity on a 4-point scale for the past week. Response choices are: "None", "Mild", "Moderate", "Severe". |
6. |
Study A: Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline over time until Week 24 [ Time Frame: Baseline to Week 24 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
7. |
Study A: Time to first response of WI-NRS ≥4 points reduction from baseline by Week 24 [ Time Frame: Baseline to Week 24 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
8. |
Study A: Absolute change from baseline in weekly average of daily WI-NRS at Week 24 [ Time Frame: Baseline to Week 24 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
9. |
Study A: Percent change from baseline in weekly average of daily WI-NRS at Week 24 [ Time Frame: Baseline to Week 24 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
10. |
Study A: Absolute change from baseline in weekly average of daily sleep disturbances numerical rating scale (NRS) at Week 12 [ Time Frame: Baseline to Week 12 ]
The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning. |
11. |
Study A: Percent change from baseline in weekly average of daily sleep disturbances NRS at Week 12 [ Time Frame: Baseline to Week 12 ]
The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning. |
12. |
Study A: Change from baseline in Dermatology Life Quality Index (DLQI) score at Week 12 [ Time Frame: Baseline to Week 12 ]
The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL. |
13. |
Study A: Change from baseline in the Itchy quality of life (ItchyQoL) score at Week 12 [ Time Frame: Baseline to Week 12 ]
ItchyQoL is a pruritus-specific QoL instrument that measures specifically disease burden in pruritus patients. |
14. |
Study A: Change from baseline in Hospital Anxiety and Depression Scale (HADS) total score at Week 12 [ Time Frame: Baseline to Week 12 ]
The HADS is a validated questionnaire for screening anxiety and depression in non-psychiatric populations. The total score ranges from 0 to 42. 0 to 7= normal; 8 to 10= borderline abnormal; 11 to 21= abnormal. |
15. |
Study A: Absolute change from baseline in weekly average of daily sleep disturbances NRS at Week 24 [ Time Frame: Baseline to Week 24 ]
The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning. |
16. |
Study A: Percent change from baseline in weekly average of daily sleep disturbances NRS at Week 24 [ Time Frame: Baseline to Week 24 ]
The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning. |
17. |
Study A: Change from baseline in DLQI score at Week 24 [ Time Frame: Baseline to Week 24 ]
The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL. |
18. |
Study A: Change from baseline in the ItchyQoL score at Week 24 [ Time Frame: Baseline to Week 24 ]
ItchyQoL is a pruritus-specific QoL instrument that measures specifically disease burden in pruritus patients. It is a 22-item instrument that measures the degree to which pruritus affects quality-of-life for the past week. The overall score is the average of the 22 items ranging from 1 to 5. A higher score corresponds to a more adverse impact on QoL. |
19. |
Study A: Change from baseline in HADS total score at Week 24 [ Time Frame: Baseline to Week 24 ]
The HADS is a validated questionnaire for screening anxiety and depression in non-psychiatric populations. The total score ranges from 0 to 42. 0 to 7= normal; 8 to 10= borderline abnormal; 11 to 21= abnormal. |
20. |
Study A: Percentage of participants experiencing treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) from baseline through end of study (EOS) [ Time Frame: Baseline to Week 36 ]
Percentage of participants experiencing TEAEs or SAEs from baseline through EOS |
21. |
Study A: Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab [ Time Frame: Baseline to Week 36 ]
Incidence of treatment-emergent ADA against dupilumab |
22. |
Study B: Proportion of participants who scored "none" or "mild" in PGIS of pruritus at Week 12 [ Time Frame: Week 12 ]
The PGIS of pruritus is a one-item categorical scale that asks participants to provide the overall self-assessment of their pruritus severity on a 4-point scale for the past week. Response choices are: "None", "Mild", "Moderate", "Severe". |
23. |
Study B: Absolute change from baseline in weekly average of daily WI-NRS at Week 12 [ Time Frame: Baseline to Week 12 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
24. |
Study B: Percent change from baseline in weekly average of daily WI-NRS at Week 12 [ Time Frame: Baseline to Week 12 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
25. |
Study B: Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline over time until Week 12 [ Time Frame: Baseline to Week 12 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
26. |
Study B: Time to first response of WI-NRS ≥4 points reduction from baseline by Week 12 [ Time Frame: Baseline to Week 12 ]
WI-NRS is a PRO comprised of a single item rated on a scale from 0 ("No itch") to 10 ("Worst imaginable itch"). |
27. |
Study B: Absolute change from baseline in weekly average of daily sleep disturbances NRS at Week 12 [ Time Frame: Baseline to Week 12 ]
The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning. |
28. |
Study B: Percent change from baseline in weekly average of daily sleep disturbances NRS at Week 12 [ Time Frame: Baseline to Week 12 ]
The sleep disturbance NRS is to be used by the participants to report the degree of their sleep loss related to itch over the past 24 hours. Participants will rate their sleep disturbance from 0 ('no sleep loss related to itch') to 10 ('I cannot sleep at all due to itch') once daily in the morning. |
29. |
Study B: Change from baseline in DLQI score at Week 12 [ Time Frame: Baseline to Week 12 ]
The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL. |
30. |
Study B: Change from baseline in the ItchyQoL score at Week 12 [ Time Frame: Baseline to Week 12 ]
ItchyQoL is a pruritus-specific QoL instrument that measures specifically disease burden in pruritus patients. It is a 22-item instrument that measures the degree to which pruritus affects quality-of-life for the past week. The overall score is the average of the 22 items ranging from 1 to 5. A higher score corresponds to a more adverse impact on QoL. |
31. |
Study B: Change from baseline in HADS total score at Week 12 [ Time Frame: Baseline to Week 12 ]
The HADS is a validated questionnaire for screening anxiety and depression in non-psychiatric populations. The total score ranges from 0 to 42. 0 to 7= normal; 8 to 10= borderline abnormal; 11 to 21= abnormal. |
32. |
Study B: Percentage of participants experiencing TEAEs or SAEs from baseline through EOS [ Time Frame: Baseline to Week 24 ]
Percentage of participants experiencing TEAEs or SAEs from baseline through EOS |
33. |
Study B: Incidence of treatment-emergent ADA against dupilumab [ Time Frame: Baseline to Week 24 ]
Incidence of treatment-emergent ADA against dupilumab |